Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
ObjectivePatients with psoriasis have an increased prevalence of type 2 diabetes when compared to the general population. Research suggests that type 2 diabetes (T2D) as well as obesity may have an impact on patients' response to treatment. This post-hoc analysis reports the efficacy of ixekizu...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2022
|
| In: |
Frontiers in medicine
Year: 2022, Jahrgang: 9, Pages: 1-8 |
| ISSN: | 2296-858X |
| DOI: | 10.3389/fmed.2022.1092688 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3389/fmed.2022.1092688 Verlag, lizenzpflichtig, Volltext: https://www.frontiersin.org/articles/10.3389/fmed.2022.1092688 
|
| Verfasserangaben: | Alexander Egeberg, Joseph F. Merola, Knut Schäkel, Luis Puig, Patrick D. Mahar, Isabella Yali Wang, Imre Pavo, Christopher Schuster and Christopher E.M. Griffiths |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1843316676 | ||
| 003 | DE-627 | ||
| 005 | 20230809103518.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230421s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmed.2022.1092688 |2 doi | |
| 035 | |a (DE-627)1843316676 | ||
| 035 | |a (DE-599)KXP1843316676 | ||
| 035 | |a (OCoLC)1389533950 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Egeberg, Alexander |d 1989- |e VerfasserIn |0 (DE-588)1185508376 |0 (DE-627)1664853316 |4 aut | |
| 245 | 1 | 0 | |a Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes |c Alexander Egeberg, Joseph F. Merola, Knut Schäkel, Luis Puig, Patrick D. Mahar, Isabella Yali Wang, Imre Pavo, Christopher Schuster and Christopher E.M. Griffiths |
| 264 | 1 | |c 2022 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 27. Januar 2023 | ||
| 500 | |a Gesehen am 21.04.2023 | ||
| 520 | |a ObjectivePatients with psoriasis have an increased prevalence of type 2 diabetes when compared to the general population. Research suggests that type 2 diabetes (T2D) as well as obesity may have an impact on patients' response to treatment. This post-hoc analysis reports the efficacy of ixekizumab in treating moderate-to-severe psoriasis in patients with prediabetes or T2D.Method and materialsUNCOVER-1, UNCOVER-2, and UNCOVER-3 were three Phase 3, multicenter, randomized, double-blind, placebo-controlled trials that evaluated the efficacy and safety of ixekizumab in adult patients with moderate-to-severe psoriasis. Patients were aged ≥18 years with chronic moderate-to-severe psoriasis (defined as ≥10% body surface area affected, static Physician Global Assessment ≥3, and Psoriasis Area and Severity Index [PASI] ≥12 at screening and baseline) who were candidates for phototherapy or systemic therapy. UNCOVER-1, UNCOVER-2, and UNCOVER-3 participants received ixekizumab as per label (that is, an initial dose of two subcutaneous injections [160 mg in total] at Week 0, followed by 80 mg every 2 weeks through Week 12 and 80 mg every 4 weeks thereafter through Week 60).ResultsThe proportions of patients with prediabetes, T2D and normoglycemia that achieved PASI75, PASI90, and PASI100 at Week 60 were similar. Results suggest that patients with T2D were slower to achieve PASI100 than patients with prediabetes or those with normoglycemia. Ixekizumab had no effect on any metabolic markers in patients receiving the treatment.ConclusionsDespite the higher rate of obesity and extreme obesity in patients with prediabetes and T2D, ixekizumab was an efficacious treatment in treating patients with psoriasis. | ||
| 700 | 1 | |a Merola, Joseph F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schäkel, Knut |e VerfasserIn |0 (DE-588)1032757418 |0 (DE-627)739272896 |0 (DE-576)251064476 |4 aut | |
| 700 | 1 | |a Puig, Luis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mahar, Patrick D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wang, Isabella Yali |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pavo, Imre |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schuster, Christopher |e VerfasserIn |4 aut | |
| 700 | 1 | |a Griffiths, Christopher E. M. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in medicine |d Lausanne : Frontiers Media, 2014 |g 9(2022), Artikel-ID 1092688, Seite 1-8 |h Online-Ressource |w (DE-627)789482991 |w (DE-600)2775999-4 |w (DE-576)408729597 |x 2296-858X |7 nnas |a Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes |
| 773 | 1 | 8 | |g volume:9 |g year:2022 |g elocationid:1092688 |g pages:1-8 |g extent:8 |a Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes |
| 787 | 0 | 8 | |i Errata |a Egeberg, Alexander, 1989 - |t Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes |d 2023 |w (DE-627)1854984101 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fmed.2022.1092688 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fmed.2022.1092688 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230421 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 1032757418 |a Schäkel, Knut |m 1032757418:Schäkel, Knut |d 910000 |d 911300 |e 910000PS1032757418 |e 911300PS1032757418 |k 0/910000/ |k 1/910000/911300/ |p 3 | ||
| 999 | |a KXP-PPN1843316676 |e 4312358788 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"2022","dateIssuedKey":"2022"}],"language":["eng"],"id":{"doi":["10.3389/fmed.2022.1092688"],"eki":["1843316676"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"disp":"Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesFrontiers in medicine","pubHistory":["2014 -"],"note":["Gesehen am 09.02.2021"],"recId":"789482991","origin":[{"publisherPlace":"Lausanne","dateIssuedDisp":"2014-","publisher":"Frontiers Media","dateIssuedKey":"2014"}],"id":{"zdb":["2775999-4"],"issn":["2296-858X"],"eki":["789482991"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"text":"9(2022), Artikel-ID 1092688, Seite 1-8","pages":"1-8","volume":"9","extent":"8","year":"2022"},"title":[{"title_sort":"Frontiers in medicine","title":"Frontiers in medicine"}],"physDesc":[{"extent":"Online-Ressource"}],"titleAlt":[{"title":"FMED"},{"title":"Front. Med."}]}],"physDesc":[{"extent":"8 S."}],"person":[{"role":"aut","given":"Alexander","family":"Egeberg","display":"Egeberg, Alexander"},{"family":"Merola","display":"Merola, Joseph F.","given":"Joseph F.","role":"aut"},{"display":"Schäkel, Knut","family":"Schäkel","given":"Knut","role":"aut"},{"display":"Puig, Luis","family":"Puig","given":"Luis","role":"aut"},{"family":"Mahar","display":"Mahar, Patrick D.","given":"Patrick D.","role":"aut"},{"given":"Isabella Yali","family":"Wang","display":"Wang, Isabella Yali","role":"aut"},{"given":"Imre","display":"Pavo, Imre","family":"Pavo","role":"aut"},{"role":"aut","family":"Schuster","display":"Schuster, Christopher","given":"Christopher"},{"role":"aut","given":"Christopher E. M.","display":"Griffiths, Christopher E. M.","family":"Griffiths"}],"title":[{"title_sort":"Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes","title":"Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes"}],"recId":"1843316676","note":["Online veröffentlicht: 27. Januar 2023","Gesehen am 21.04.2023"],"name":{"displayForm":["Alexander Egeberg, Joseph F. Merola, Knut Schäkel, Luis Puig, Patrick D. Mahar, Isabella Yali Wang, Imre Pavo, Christopher Schuster and Christopher E.M. Griffiths"]}} | ||
| SRT | |a EGEBERGALEEFFICACYOF2022 | ||